Current insights into the "antiphospholipid" syndrome: Clinical, immunological, and molecular aspects

Advances in Immunology

Volumn 70, Issue , 1998, Pages 507-563

  Kandiah, David A ^a   Sali, Andrej ^b   Sheng, Yonghua ^a   Victoria, Edward J ^c   Marquis, David M ^c   Coutts, Stephen M ^c   Krilis, Steven A ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ROCKEFELLER UNIVERSITY   (United States)

^c La Jolla Pharmaceutical Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BETA2 GLYCOPROTEIN 1; EPITOPE; LUPUS ANTICOAGULANT; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTHROMBIN;

ANTIBODY STRUCTURE; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; AVASCULAR NECROSIS; CLINICAL FEATURE; ELECTROCHEMISTRY; ENDOTHELIUM CELL; ENZYME ACTIVATION; EPITOPE MAPPING; HUMAN; IMMUNOGENICITY; IMMUNOPATHOGENESIS; LABORATORY DIAGNOSIS; MOLECULAR CLONING; MOLECULAR MODEL; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; REVIEW; SEQUENCE HOMOLOGY; SPECIES DIFFERENCE;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; FEMALE; GLYCOPROTEINS; HUMANS; LUPUS COAGULATION INHIBITOR; MALE; MODELS, MOLECULAR; PREGNANCY;

EID: 0033490814     PISSN: 00652776     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (253)

1. Abola, E. E., Bernstein, F. C, Bryant, S. H., Koetzle, T., and Weng, J. (1987). In "Crystallographic Databases: Information, Content, Software Systems, Scientific Applications" (F. H. Allen, G. Bergerhoff, and R. Sievers, eds.), pp. 107-132. Data Commission of the International Union of Crystallography, Cambridge/Chester.
2. Adrianakos, A. A., Duffy, U. J., Suzuki, M., and Sharp, J. J. (1975). Transverse myelopathy in systemic lupus erythematosus: A report of three cases and a review of the literature. Ann. Intern. Med. 83, 616-624.
3. Alarcon-Segovia, D., and Osmundson, P. J. (1965). Peripheral vascular syndromes associated with systemic lupus erythematosus. Ann. Intern. Med. 62, 907-919.
4. Alarcon-Segovia, D., Perez-Vasquez, M. E., Villa, A. R., Drenkard, C, and Cabiedes, J. (1992). Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin. Arthritis Rheum. 21, 275-286.
5. Alarcon-Segovia, D., and Sanchez-Guerrero, J. (1989). Primary antiphospholipid syndrome. J. Rheumatol. 16, 482-486.
6. Alegre, V. A., Gastineau, D. A., and Winkelmann, R. K. (1989). Skin lesions associated with circulating lupus anticoagulant. Br. J. Dermatol. 120, 419-429.
7. Alegre, V. A., and Winkelmann, R. K. (1988). Histopathologic and immunofluorescence study of skin lesions associated with circulating anticoagulant. J. Am. Acad. Dermatol. 19, 117-124.
8. Anderson, D., Bell, D., Lodge, R., and Grant, E. (1987). Recurrent cerebral isehaemia and mitral valve vegetation in a patient with lupus anticoagulant. J. Rheumatol. 14, 839-841.
9. The Antiphospholipid Antibodies in Stroke Study Group (APASS) (1990). Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral isehaemia. Stroke 21, 1268-1273.
10. APASS (1993). Anticardiolipin antibodies are an independent risk factor for first ischaemie stroke. Neurology 43, 2069-2073.
11. Aoki, K., Dudkiewicz, A. B., Matsuura, E., Novotny, M., Kaberlein, G., and Gleicher, N. (1995). Clinical significance of β2-glycoprotein I dependent anticardiolipin antibodies in the reproductive autoimmune failure syndrome: Correlation with conventional antiphospholipid antibody detection systems. Am. J. Obstet. Gynaecol. 172, 926-931.
12. Aoyama, Y., Chan, Y. L., and Wool, I. G. (1989). The primary structure of rat β2-glycoprotein I. Nucleic Acids Res. 17, 6401.
13. Arnold, M. H., and Schrieber, L. (1988). Splenic and renal infarction in systemic lupus erythematosus: Association with anticardiolipin antibodies. Clin. Rheumatol. 7, 406-410.
14. Aron, A. L., Cuellar, M. L., Brey, R. L., Mckeown, S., Espinoza, L. R., Shoenfeld, Y., and Gharavi, A. E. (1995). Early onset of autoimmunity in MRL/++ mice following immunization with beta 2-glycoprotein I. Clin. Exp. Immunol. 101, 78-81.
15. Arvieux, J., Roussel, B., Ponard, D., and Colomb, M. G. (1994). IgG2 subclass restriction of anti-β2 glycoprotein I antibodies in autoimmune patients. Clin. Exp. Immunol. 95, 310-315.
16. Arvieux, J„ Darnige, L„ Caron, C, Reber, G., Bensa, J. C, and Colomb, M. G. (1995). Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb. Haemostasis 74, 1120-1125.
17. Arvieux, J., Daniige, L., Hachulla, E., Roussel, B., Bensa, J. C., and Colomb, M. G. (1996). Species specificity of anti-β2 glycoprotein I autoantibodies and its relevance to anticardiolipin antibody quantitation. Thromb. Haemostasis 75, 725-730.
18. Asherson, R. A. (1988). A "primary" antiphospholipid syndrome?J. Rheumatol. 15, 1742-1746.
19. Asherson, R. A. (1992). The catastrophic antiphospholipid syndrome. J. Rheumatol. 19, 508-512.
20. Asherson, R. A. (1993). Antiphospholipid antibodies and the kidney. J. Rheumatol. 20,1268-1272.
21. Asherson, R. A. (1994). Hypoadrenalism and antiphospholipid antibodies: A new cause of "idiopathic" Addison's disease. In "Advances in Thomas Addison's Diseases" (Bhatt, James, Besser, Botazzo, and Keen, eds.), pp. 87-101. Journal of Endocrinology, Bristol, England.
22. Asherson, R. A., and Cervera, R. (1992). The antiphospholipid syndrome: A syndrome in evolution. Ann. Rheum. Dis. 51, 147-150.
23. Asherson, R. A., Harris, E. N., Gharavi, A. E., and Hughes, G. R. V. (1986a). Systemic lupus erythematosus, antiphospholipid antibodies, chorea and oral contraceptives. Arthritis Rheum. 29, 1533-1536.
24. Asherson, R. A., Higenbottam, T. W., Dinh Xuan, A. T., Khamashta, M. A., and Hughes, G. R. V. (1990). Pulmonary hypertension in a lupus clinic: Experience with twenty-four patients. J. Rheumatol. 17, 1292-1296.
25. Asherson, R. A., and Hughes, G. R. V. (1988). Antiphospholipid antibodies in chorea. J. Rheumatol. 15, 377-379.
26. Asherson, R. A., and Hughes, G. R. V. (1989). Recurrent deep vein thrombosis and Addison's disease in "primary" antiphospholipid syndrome. J. Rheumatol. 16, 378-380.
27. Asherson, R. A., Khamashta, M. A., Ordi-Ros, J., Derksen, R. H. W. M., Machin, S. J., Barquinero, J., Outt, H. H„ Harris, E. N., Vilardell-Tarres, M., and Hughes, G. R. V. (1989). The "primary" antiphospholipid syndrome: Major clinical and serological features. Medicine 68, 366-374.
28. Asherson, R. A., Mackworth-Young, C. G., Harris, E., Gharavi, A. E., and Hughes, G. R. V. (1985). Multiple venous and arterial thromboses associated with the lupus anticoagulant and antibodies to cardiolipin in the absence of SLE. Rheumatol. Int. 5, 91-93.
29. Asherson, R. A., Morgan, S. H., Harris, E. N., Gharavi, A. E., Kraus, T., and Hughes, G. R. V. (1986b). Arterial occlusion causing large bowel infarction: A reflection of clotting diathesis in SLE. Clin. Rheumatol. 5, 102-106.
30. Auger, W. R., Permpikul, P., and Moser, K. M. (1995). Lupus anticoagulant, heparin use, and thrombocytopenia in patients with chronic thromboembolic pulmonary hypertension: A preliminary report. Am. J. Med. 99, 392-396.
31. Bajaj, S. P., Rapaport, S. I., Fierer, D. S., Herbst, K. D., and Schwartz, D. B. (1983). A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 61, 684-692.
32. Bakimer, R., Fishman, P., Blank, M., Sredni, B., Djaldetti, M., and Shoenfeld, Y. (1992). Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J. Clin. Invest. 89, 1558-1563.
33. Balestrieri, G., Tincani, A., Spatola, L., Allegri, F., Prati, E., Cattaneo, R., Valesini, G., Del Papa, N., and Meroni, P. (1995). Anti-β2-gIycoprotein I antibodies: A marker of the antiphospholipid syndrome? Lupus 4, 122-130.
34. Barlow, P. N., Steinkasserer, A., Norman, D. G., Kieffer, B., Wiles, P., Sim, R. B., and Campbell, I. D. (1993). Solution structure of a pair of complement modules by nuclear magnetic resonance. J. Mol. Biol. 232, 268-284.
35. Bendixen, E., Halkier, T., Magnusson, S., Sottrup-Jensen, L., and Kristensen, T. (1992). Complete primary structuring of bovine beta2-glycoprotein I: Localisation of the disulphide bridges. Biochemistry 31, 3611-3617.
36. Bevers, E. M., Galli, M., Barbui, T., Comfurius, P., and Zwaal, R. F. A. (1991). Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb. Haemostasis 66, 629-632.
37. Bilofsky, H. S., and Burks, C. (1988). The GenBank genetic sequence data bank. Nucleic Acids Res. 16, 1861-1863.
38. Biou, V., Gibrat, J.-F., Levin, J. M., Robson, B., and Gamier, J. (1988). Secondary structure prediction: Combination of three different methods. Prot. Eng. 2, 185-191.
39. Blank, M., Cohen, J., Toder, V., and Shoenfeld, Y. (1991). Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc. Natl. Acad. Sci. USA 88, 3069-3073.
40. Blank, M., Faden, D., Tincani, A., Kopolovic, J., Goldberg, I., Gilburd, B., Allegri, F., Balestrieri, G., Valesini, G., and Shoenfeld, Y. (1994b). Immunization with anticardiolipin cofaetor (beta-2-gIycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J. Autoimmun. 7, 441-455.
41. Blank, M., Tincani, A., and Shoenfeld, Y. (1994a). Induction of experimental antiphospholipid syndrome in naive mice with purified IgG antiphosphatidylserine antibodies.J. Rheumatol. 21, 100-104.
42. Boey, M. L., Colaco, C. B., Gharavi, A. E., Elkon, K. B., Loizou, S., and Hughes, G. R. V. (1983). Thrombosis in systemic lupus erythematosus: Striking association with the presence of circulating lupus anticoagulant. Br. Med. J. 287, 1021-1023.
43. Bokarewa, M. I., Bremme, K., Falk, G., Sten-Linder, M., Egberg, N., and Blomback, M. (1995). Studies on phospholipid antibodies, APC-resistance and associated mutation in the coagulation factor V gene. Thromb. Res. 78, 193-200.
44. Bowie, E. J. W., Thompson, J. H., Jr., Pascuzzi, C. A., and Owen, C. A., Jr. (1963). Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J. Lab. Clin. Med. 62, 416-430.
45. Branch, D. W. (1990). Antiphospholipid antibodies and pregnancy: Maternal implications. Semin. Perinatal. 14, 139-146.
46. Branch, D. W., Dudley, D. J„ Mitchell, M. D., Creighton, K. A., Abbott, T. M., Hammond, E. H., and Daynes, R. A. (1990). Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: A model for autoimmune fetal loss. Am. J. Obstet. Gynaecol. 163, 210-216.
47. Brandt, J. T., Triplett, D. A„ Alving, B., and Scharrer, I. (1995). Criteria for the diagnosis of lupus anticoagulants: An update. Thromb. Haemostasis 74, 1185-1190.
48. Brey, R. L., Hart, R. G„ Sherman, D. G., and Tegeler, C. T. (1990). Antiphospholipid antibodies and cerebral ischaemia in young people. Neurology 40, 1190-1196.
49. Briley, D. P., Coull, B. M., and Goodnight, S. H. (1989). Neurologic disease associated with antiphospholipid antibodies. Ann. Neurol. 25, 221-227.
50. Buchberg, A. M., Brownell, E., Nagata, S., Jenkins, N. A., and Copeland, N. G. (1989). A comprehensive generic map of murine chromosome 11 reveals extensive linkage conservation between mouse and human. Genetics 122, 153-161.
51. Cabiedes, J., Cabral, A. R., and Alarcon-Segovia, D. (1995). Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-β2-glycoprotein-I than with antiphospholipid antibodies. J. Rheumatol. 22, 1899-1906.
52. Cariou, R., Tobelem, G., Bellucci, S., Soria, J., Maclouf, J., and Caen, J. (1988). Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells: Inhibition of thrombomodulin-dependent protein C activation. Thromb. Haemostasis 60, 54-58.
53. Caruso, A., De Carolis, S., Ferrazzani, F., Valesini, G., Caforio, L., and Mancuso, S. (1993). Pregnancy outcome in relationship to uterine artery flow velocity waveforms and clinical characteristics in women with antiphospholipid syndrome. Obstet. Gynaecol. 82,970-977.
54. Celli, C. M., Gharavi, E. E., Cucurull, E., Espinoza, L. R., Chimovich, H., and Gharavi, A. E. (1997). β2-glyeoprotein I and phospholipid-binding viral peptides interaction with cardiolipin-containing liposomes. Arthritis Rheum. 40(9), Suppl. 314 [Abstract 1700]
55. Cervera, R., Font, J., Pare, C, Azqueta, M., Perez-Villa, F., Lopez-Soto, A., and Ingelmo, M. (1992). Cardiac disease in systemic lupus erythematosus: Prospective study of 70 patients. Ann. Rheum. Dis. 51, 156-159.
56. Chamley, L. W., Allen, J. L., and Johnson, P. M. (1997). Synthesis of beta 2-glycoprotein I by the human placenta. Placenta 18, 403-410.
57. Chamley, L. W., Pattison, N. S., and McKay, E. J. (1993). Elution of anticardiolipin antibodies and their cofactor beta 2-glycoprotein I from the placentae of patients with a poor obstetric history. J. Reprod. Immunol. 25, 209-220.
58. Chandonia, J. M., and Karplus, M. (1996). The importance of larger data sets for protein secondary structure prediction with neural networks. Prot. Sci. 5, 768-774.
59. Clark, E., and Ledbetter, J. (1994). How B and T cells talk to each other. Nature 367, 425-428.
60. Conley, C. L., and Hartmann, R. C. (1952). A haemorrhagic disorder caused by a circulating anticoagulant in patients with disseminated lupus erythematosus.J. Clin. Invest. 31, 621.
61. Cote, S. A., Brey, R. L., and Teale, J. M. (1994). Autoimmune neurological disease is accelerated in MRL/+ + mice after apolipoprotein H (Apo H) immunization. Lupus 3,97.
62. Courts, S. M., Plunkett, M. L., Iverson, G. M., Barstad, P. A., and Berner, C. M. (1996). Pharmacological intervention in antibody mediated disease. Lupus 5, 158-159.
63. de la Paz, P., Sutton, B. J., Darsley, M. J., and Rees, A. R. (1986). Modelling of the combining sites of three anti-lysozyme monoclonal antibodies and of the complex between one of the antibodies and its epitope. EMBO J. 5, 415-425.
64. Del Papa, N., Guidali, L., Sala, A., Buccellati, C, Khamashta, M. A., Ichikawa. K., Koike, T., Balestrieri, G., Tincani, A., Hughes, G. R. V., and Meroni, P. L. (1997). Endothelial cells as target for antiphospholipid antibodies: Human polyclonal and monoclonal antiβ2-glycoprotein I antibodies react in vitro with endothelial cells through adherent β2-glycoprotein I and induce endothelial activation. Arthritis Rheum. 40, 551-561.
65. Del Papa, N., Guidali, L., Spatola, L., Bonra, P., Borghi, M. O., Tincani, A., Balestrieri, G., and Meroni, P. L. (1995). Relationship between anti-phospholipid and anti-endothelial antibodies III: β2-glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin. Exp. Rheumatol. 13, 179-186.
66. Del Papa, N., Meroni, P. L., Tincani, A., Harris, E. N., Pierangeli, S. S., Barcellini, W., Borghi, M. O., Balestrieri, G., and Zanussi, C. (1992). Relationship between antiphospholipid and antiendothelial antibodies: Further characterization of the reactivity on resting and cytokine-acrivated endothelial cells. Clin. Exp. Rheumatol. 10, 37-42.
67. Del Papa, N., Sheng, Y., Raschi, E., Kandiah, D. A., Tincani, A., Khamashta, M. A., Hughes, G. R. V., Koike, T., Balestrieri, G., Krilis, S. A., and Meroni, P. L. (1998). Human β2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for binding anionic phospholipids and offers epitopes for anti-β2-glycoprotein I antibodies. J. Immunol, in press.
68. De Wolf, F., Carreras, L. O., Moerman, P., Vermylen, J., Van Assche, A., and Renaer, M. (1982). Decidual vasculopathy and extensive placental infarction patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am. J. Obstet. Gynaecol. 142, 829-834.
69. Erlendsson, K., Steinsson, K., Johansson, J. H., and Geirsson, R. T. (1993). Relation of antiphospholipid antibody and placental bed inflammatory vascular changes to the outcome of pregnancy in successive pregnancies of 2 women with SLE. J. Rheumatol. 20, 1779-1785.
70. Ermel, L. D., Marshburn, P. B., and Kutteh, W. H. (1995). Interaction of heparin with antiphospholipid antibodies (APA) from the sera of women with recurrent pregnancy loss (RPL). Am. J. Reprod. Immunol. 33, 14-20.
71. Farrugia, E., Torres, V. E., Gastineau, D., Michet, C. J., and Holley, K. E. (1992). Lupus anticoagulant in systemic lupus erythematosus: A clinical and renal pathological study. Am. J. Kidney Dis. 20, 463-471.
72. Fatenejad, S., Mamula, M. J., and Craft, J. (1993). Role of intermolecular/intrastructural B- and T-cell determinants in the diversification of autoantibodies to ribonucleoprotein particles. Proc. Natl. Acad. Sci. USA 90, 12010-12014.
73. Fearon, D. T. (1991). Anti-inflammatory and immunosuppressive effects of recombinant soluble complement receptors. Clin. Exp. Immunol. 86(Suppl. 1), 43-46.
74. Felsenstein, J. (1985). Confidence limits on phylogenies: An approach using the bootstrap. Evolution 39, 783-791.
75. Fleck, R. A., Rapaport, S. I., and Rao, L. V. (1988). Anti-prothrombin antibodies and the lupus anticoagulant. Blood 72, 512-519.
76. Forastiero, R. R., Martinuzzo, M. E., Cerrato, G. S., Kordich, L. C, and Carreras, L. O. (1997). Relationship of anti-β2-glycoprotein I and anti-prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb. Haernostasis 78, 1008-1014.
77. Ford, P. M., Ford, S. E., and Lillicrap, D. P. (1988). Association of lupus anticoagulant with severe valvular heart disease in systemic lupus erythematosus.J. Rheumatol. 15,597-600.
78. Fujisao, S., Matsushita, S., Nishi, T., and Nishimura, Y. (1996). Identification of HLA-DR9 (DRB1 * 0901)-binding peptide motifs using a phage random peptide library. Hum. Immunol. 45, 131-136.
79. Galli, M., Beretta, G., Daldossi, M., Bevers, E. M., and Barbui, T. (1997). Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb. Haernostasis 77, 486-491.
80. Galli, M., Bevers, E. M., Comfurius, P., Barbui, T., and Zwaal, R. F. A. (1993). Effect of anti-phospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br. J. Haematol. 83, 466-472.
81. Galli, M., Comfurius, P., Barbui, T., Zwaal, R. F., and Bevers, E. M. (1992). Anticoagulant activity of beta 2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb. Haernostasis 68, 297-300.
82. Galli, M., Comfurius, P., Massen, C, Hemker, H. C, deBaets, M. H., van Breda-Vriesman, P. J. C, Barbui, T., Zwaal, R. F. A. and Bevers, E. M. (1990). Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335,1544-1547.
83. Galli, M., Finazzi, G., Bevers, E. M., and Barbui, T. (1995). Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and /32-glycoprotein I-dependent antiphospholipid antibodies. Blood 86, 617-623.
84. Gavaghan, T. P., Krilis, S. A., Daggard, G. E., Baron, D. W., Hickie, J. B., and Chesterman, C. N. (1987). Anticardiolipin antibodies and occlusion of coronary artery bypass grafts. Lancet 2, 977-978.
85. Gharavi, A. E., Mellors, R. C, and Elkon, K. B. (1989). IgG anticardiolipin antibodies in murine lupus. Clin. Exp. Immunol. 78, 233-238.
86. Ghosh, S., Walters, H. D., Joist, J. H., Osbom, T. G., and Moore, T. L. (1993). Adult respiratory distress syndrome associated with antiphospholipid syndrome. J. Rheumatol. 20, 1406-1408.
87. Gleicher, N. (1994). Autoantibodies and pregnancy loss. Lancet 343, 747-748.
88. Goldstein, S. R. (1994). Embryonic death in early pregnancy: A new look at the first trimester. Obstet. Gynaecol. 84, 294-297.
89. Grennan, D. M., McCormick, J. N., Wojtacha, D., Carty, M., and Behan, W. (1978). Immunological studies of the placenta in systemic lupus erythematosus. Ann. Rheum. Dis. 37, 129-134.
90. Grottolo, A., Ferari, V., Mariarosa, M., Sambruni,. A., Tincani, A., and Del Bono, R. (1988). Primary adrenal insufficiency, circulating lupus anticoagulant and anticardiolipin antibodies in a patient with multiple abortions and recurrent thrombotic episodes. Haematologia 73, 517-519.
91. Haagerup, A., Kristensen, T., and Kruse, T. A. (1991). Polymorphism and genetic mapping of the gene encoding human β2-glycoprotein I to chromosome 17. Cytogenet. Cell Genet. 58, 2004-2010.
92. Hajjar, K. A., Gavish, D., Breslow, J. L., and Nachman, R. L. (1989). Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 339, 303-305.
93. Hang, L. M., Izui, S., and Dixon, F. J. (1981). (NZW x BXSB)F1 hybrid: A model of acute lupus and coronary vascular disease with myocardial infarction.J. Exp. Med. 154,216-221.
94. Harris, E. N., Chan, T. K.. Asherson, R. A., Aber, V. R., Gharavi, A. E., and Hughes, G. R. V. (1986). Thrombosis, recurrent fetal loss and thrombocytopenia: Predictive value of the anticardiolipin antibody test. Arch. Intern. Med. 146, 2153-2156.
95. Harris, E. N., Gharavi, A. E., Asherson, R. A., Boey, M. L., and Hughes, G. R. V. (1984). Cerebral infarction in systemic lupus: Association witii anticardiolipin antibodies. Clin. Exp. Rheum. 25, 1271-1277.
96. Harris, E. N., Pierangeli, S., and Birch, D. (1994). Anticardiolipin wet workshop report (fifth international symposium on antiphospholipid antibodies). Am. J. Clin. Pathol. 101, 616-624.
97. Hasegawa, I., Takakuwa, K., Adachi, S., and Kanazawa, K. (1990). Cytotoxic antibody against trophoblast and lymphocytes present in pregnancy with intrauterine fetal growth retardation and its relation to anti-phospholipid antibody. J. Reprod. Immunol. 17, 127-139.
98. Hashimoto, Y., Kawamura, M., Ichikawa, K., Suzuki, T., Sumida, T., Yoshida, S., Matsuura, E., Ikehara, S., and Koike, T. (1992). Anticardiolipin antibodies in NZWx BXSB/F1 mice. J. Immunol. 149, 1063-1068.
99. Hasselaar, P., Derksen, R. H. W. M., Blokzijl, L., and de Groot, P. G. (1990). Cross-reactivity of antibodies directed against cardiolipin, DNA, endothelial cells and blood platelets. Thromb. Haemostasis 63, 169-173.
100. Hasselaar, P., Derksen, R. H. W. M., Oosting, J. D., Blokzijl, L., and de Groot, P. G. (1989). Synergistic effect of low doses of tumor necrosis factor and sera from patients with systemic lupus erythematosus on the expression of procoagulant activity by cultured endothelial cells. Thromb. Haemostasis 62, 654-660.
101. Hering, R., Couturier, E. G. M., Asherson, R. A., and Steiner, T. J. (1991). Antiphospholipid antibodes in migraine. Cephalalgia 11, 19-20.
102. Herranz, M. T., Rivier, G., Khamashta, M. A., Blaser, K. U., and Hughes, G. R. V. (1994). Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum. 37, 568-571.
103. Hochberg, M. C. (for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology) (1997). Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40, 1725. [letter]
104. Horbach, D. A., van Oort, E., Donders, R. C. J. M., Derksen, R. H. W. M., and de Groot, P. G. (1996). Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Thromb. Haemostasis 76, 916-924.
105. Horellou, M. H., Aurousseau, M. H., Boffa, M. C, Conrad, J., Wiesel, M. L., and Samama, M. (1987). Biological and clinical heterogeneity of lupus and lupus-like anticoagulant in fifty-seven patients. J. Med. 18, 199-217.
106. Howe, H. S., Boey, M. L., Fong, K. Y., and Feng, P. H. (1988). Pulmonary haemorrhage, pulmonary infarction, and the lupus anticoagulant. Ann. Rheum. Dis. 47, 869-872.
107. Hughes, G. R. V. (1983). Thrombosis, abortion, cerebral disease and the lupus anticoagulant. Br. Med. J. 287, 1088-1089.
108. Hughes, G. R. V. (1985). The anticardiolipin syndrome. Clin. Exp. Rheumatol. 3, 285-286.
109. Hughes, G. R. V., Harris, E. N., and Gharavi, A. E. (1986). The anticardiolipin syndrome. J. Rheumatol. 13, 486-489.
110. Hunt, J. E., McNeil, H. P., Morgan G. J., Crameri, R. M., and Krilis S. A. (1992). A phospholipid-β2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1, 83-90.
111. Hunt, J. E., Simpson, R. J., and Krilis, S. A. (1993). Identification of a region of β2-glyeoprotein I critical for lipid-binding and anticardiolipin cofactor activity. Proc. Natl. Acad. Sci. USA 90, 2141-2145.
112. Hunt, J. E., and Krilis, S. A. (1994). The fifth domain of β2-glycoprotein I contains a phospholipid-binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J. Immunol. 152, 653-659.
113. Kamboh, M. I., Wagenknecht, D. R., and Mclntyre, J. A. (1995). Heterogeneity of apolipoprotein H°3 allele and its role in affecting the binding of apolipoprotein H (/32-glycoprotein I) to anionic phospholipids. Hum. Genet. 95, 385-388.
114. Kandiah, D. A., and Krilis, S. A. (1994). Beta2-glycoprotein I. Lupus 3, 207-212.
115. Kandiah, D. A., and Krilis, S. A. (1996a). Immunology and methods of detection of antiphospholipid antibodies. In "The Antiphospholipid Syndrome" (R. A. Asherson, R. Cervera, J.-C. Pierte, and Y. Shoenfeld, eds.), pp. 29-48. CRC Press, Boca Raton, FL.
116. Kandiah, D. A., and Krilis, S. A. (1996b). Laboratory detection of antiphospholipid antibodies. Lupus 5, 160-162.
117. Kandiah, D. A., and Krilis, S. A. (1997a). Affinity-purified anti-prothrombin antibodies in the antiphospholipid syndrome: Immunological specificity and clotting profiles. Arthritis Rheum. 40(9), Suppl., 104. [Abstract 443]
118. Kandiah, D. A., and Krilis, S. A. (1997b). The clotting assays dilute Russell's viper venom time (dRWT) and dilute kaolin clotting time (dKCT) detect different populations of antibodies in plasmas of individual patients with lupus anticoagulant activity. Arthritis Rheum. 40(9), suppl., 298. [Abstract 1604]
119. Kang, I., Craft, J., and Bockenstedt, L. K. (1997). αβ T-helper cell and CD40 ligand dependency in the development of anticardiolipin antibody. Arthritis Rheum. 40(9), Suppl., 314. [Abstract 1701]
120. Kant, K. S., Pollak, V. E., Weiss, M. A., Glueck, H. I., Miller, M. A., and Hess, E. V. (1981). Glomerular thrombosis in systemic lupus erythematosus: Prevalence and significance. Medicine 60, 71-86.
121. Keeling, D. M., Wilson, A. J., Mackie, I. J., Isenberg, D. A., and Machin, S. J. (1993). Role of beta 2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro.J. Clin. Pathol. 46, 908-911.
122. Kertesz, Z, Yu, B. B., Steinkasserer, A., Haupt, H., Benham, A., and Sim, R. B. (1995). Characterization of binding of human beta 2-glycoprotein I to cardiolipin. Biochem. J. 310, 315-321.
123. Khamashta, M. A., Cervera, R., Asherson, R. A., Font, J., Gil, A., Coltart, D. J., Vazquez, J. J., Pare, C., Ingelmo, M., Oliver, J., and Hughes, G. R. V. (1990). Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 335, 1541-1544.
124. Kochl, S., Fresser, F., Lobentanz, E., Baier, G., and Utermann, G. (1997). Novel interaction of apolipoprotein(a) with β2-glycoprotein I mediated by the kringle IV domain. Blood 90, 1482-1489.
125. Kouts, S., Wang, M. X., Adelstein, S., and Krilis, S. A. (1995). Immunization of a rabbit with β2-glycoprotein I induces charge-dependent crossreactive antibodies that bind anionic phospholipids and have similar reactivity as autoimmune antiphospholipid antibodies. J. Immunol. 155, 958-966.
126. Kristensen, T., Schousboe, I., Boel, E., Mulvihill, E. M., Hansen, R. R., Moller, K. B., Moller, N. P. H., and Sottrap-Jensen, L. (1991). Molecular cloning and mammalian expression of human beta 2-glycoprotein I cDNA. FEBS Lett. 289, 183-186.
127. Kroll, J., Larsen, J. K., Loft, H., Ezban, M., Wallevik, K., and Faber, M. (1976). DNA-binding proteins in Yoshida ascites tumour fluid. Biochim. Biophys. Acta 434, 490-501.
128. Laker, M. F., and Evans, E. (1996). Analysis of apolipoproteins. Ann. Clin, Biochem. 33, 5-22.
129. La Rosa, L., Meroni, P. L., Tincani, A., Balestrieri, G., Faden, A., Lojacono, A., Morassi, L., Brocchi, E., Del Papa, N., Gharavi, A. E., Sammaritano, L., and Lockshin, M. A. (1994). β2-glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. J. Rheumatol. 21, 1684-1698.
130. Lavalle, C., Pizarro, S., Drenkard, C., Sanchez-Guerrero, J., and Alarcon-Segovia, D. (1990). Transverse myelitis: Manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J. Rheumatol. 17, 34-37.
131. Lee, N. S., Brewer, H. B., and Osborne, J. C. J. (1983). Beta 2-glycoprotein I: Molecular properties of an unusual apolipoprotein, apolipoprotein H.J. Biol. Chem. 258,4765-4770.
132. Lehmann, P. V., Sercarz, E. E., Forsthuber, T., Dayan, C. M., and Gammon, G. (1993). Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol. Today 14, 203-208.
133. Le Tonqueze, M., Dueymes, M., and Piette, J. C. (1995). Is there a role for /32-glycoprotein I in the anti-phospholipid binding to endothelial cells. Lupus 4, 179-186.
134. Leung, W. H., Wong, K. L., Lau, C. P., Wong, C. K., and Cheng, C. H. (1990). Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am. J. Med. 89, 411-419.
135. Levine, S. R., Deegan, M. J., Futrell, N., and Welch, K. M. A. (1990). Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 40, 1181-1189.
136. Levine, S. R., Kieran, S., Puzio, K., Feit, H., Patel, S. C, and Welch, K. M. A. (1987). Cerebral venous thrombosis with lupus anticoagulants. Stroke 18, 801-804.
137. Levine, S. R., Salowich-Palm, L., Sawaya, K. L., Perry, M., Spencer, H. J., Winkler, H. J., Alam, Z., and Carey, J. L. (1997). IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death: A prospective cohort study. Stroke 28, 1660-1665.
138. Lockshin, M. D., Druzin, M. L., Goei, S., Qamar, T., Magid, M. S., Jovanovic, L., and Ferenc, M. (1985). Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N. Engl. J. Med. 313, 152-156.
139. Loeliger, A. (1959). Prothrombin as cofactor in the circulating anticoagulant in systemic lupus erythematosus? Thromb. Diath. Haemorrh. 3, 237.
140. Loizou, S., McCrea, J. D., Rudge, A., Reynolds, A., Boyle, C. C, and Harris, E. N. (1985). Measurement of anticardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): Standardisation and quantitation of results. Clin. Exp. Immunol. 62, 738-745.
141. Lozier, J., Takahashi, N., and Putnam, F. W. (1984). Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc Natl. Acad. Sci. USA 81, 3640-3644.
142. Lubbe, W. F., and Walker, E. B. (1983). Chorea gravidarum associated with circulating lupus anticoagulant: Successful outcome of preganncy with prednisone and aspirin therapy. Br. J. Obstet. Gynaecol. 90, 487-490.
143. Lusins, J. O., and Szilagyi, P. A. (1975). Clinical features of chorea associated with systemic lupus erythematosus. Am. J. Med. 58, 857-861.
144. Luthy, R., Bowie, J, U,, and Eisenberg, D. (1992). Assessment of protein models with three-dimensional profiles. Nature 356, 83-85.
145. Mackworth-Young, C. G., Gharavi, A. E., Boey, M. L., and Hughes, G. R. V. (1984). Portal and pulmonary hypertension in a case of systemic lupus erythematosus: Possible relationship with a clotting abnormality. Eur. J. Rheum. Inflam. 7, 71-74.
146. Mamula, M., and Janeway, C. (1993). Do B cells drive the diversification of immune responses? Immunol. Today 14, 151-153.
147. Mandreoli, M., Zuccala, A., and Zucchelli, P. (1992). Fibromuscular dysplasia of the renal arteries associated with antiphospholipid autoantibodies: Two case reports. Am. J. Kidney Dis. 20, 500-503.
148. Marie, I, Levesque, H., Heron, F., Cailleux, N., Borg, J. Y., and Courtois, H. (1997). Acute adrenal failure secondary to bilateral infarction of the adrenal glands as the first manifestation of primary antiphospholipid syndrome. Ann. Rheum. Dis. 56, 567-568. [Letter]
149. Martinuzzo, M. E., Forastiero, R. R., and Carreras, L. O. (1995). Anti-β2-glycoprotein I antibodies: Detection and association with thrombosis. Br. J. Haematol 89, 397-402.
150. Matsuda, J., Gohchi, K., Tsukamoto, M., Saitoh, N., Asami, K., and Hashimoto, M. (1993). Anticoagulant activity of an anti-β2-glycoprotein I antibody is dependent on the presence of β2 glycoprotein I. Am. J. Haematol. 44, 187-191.
151. Matsumoto, A. K., Kopicky-Burd, J., Carter, R. H., Tuveson, D.A., Tedder, T. F., and Fearon, D. T. (1991). Intersection of the complement and immune systems: A signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J. Exp. Med. 173, 55-64.
152. Matsuura, E., Igarashi, Y., Yasuda, T., Triplett, D. A., and Koike, T. (1994). Anticardiolipin antibodies recognise β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J. Exp. Med, 179, 457-462.
153. Mbewu, A. D., and Durrington, P. N. (1990). Lipoprotein(a): Structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis 85, 1-14.
154. McCrae, K. R., DeMichele, A. M., Pandhi, P., Balsai, M. J., Samuels, P., Graham, C., Lala, P. K., and Cines, D. B. (1993). Detection of antitrophoblast antibodies in the sera of patients with anticardiolipin antibodies and fetal loss. Blood 82, 2730-2741.
155. McLean, J. W., Tomlinson, J. E., Kuang, W. J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., and Lawn, R. M. (1987). cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330, 132-137.
156. McNally, T., Cotterell, S. E., Mackie, I. J., Isenberg, D. A., and Machin, S. J. (1994). The interaction of β2 glycoprotein-I and heparin and its effect on β2 glycoprotein I antiphospholipid antibody cofactor function in plasma. Thromb. Haemostasis 72,578-581.
157. McNeil, H. P., Chesterman, C. N., and Krilis, S. A. (1989). Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics. Br. J. Haematol. 73, 506-513.
158. McNeil, H. P., Chesterman C. N., and Krilis, S. A. (1991). Immunology and clinical importance of antiphospholipid antibodies. Adv. Immunol. 49, 193-280.
159. McNeil, H. P., Simpson, R. J., Chesterman, C. N., and Krilis, S. A. (1990). Antiphospholipid antibodies are directed to a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc. Natl. Acad. Sci. USA 87, 4120-4124.
160. Miles, L. A., Fless, G. M., Levin, E. G., Scanu, A. M., and Plow, E. F. (1989). A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 339, 301-303.
161. Mizutani, H., Kurata, Y., Kosugi, S., Shiraga, M., Kashiwagi, H., Tomiyama, Y., Kanakura, Y., Good, R. A., and Matsuzawa, Y. (1995). Monoclonal anticardiolipin autoantibodies established from the (NZW x BXSB)F1 mouse model of antiphospholipid syndrome cross-react with oxidised low-density lipoprotein. Arthritis Rheum. 38, 1382-1388.
162. Moll, S., and Ortel, T. L. (1997). Monitoring warfarin therapy in patients with lupus anticoagulants. Ann. Int. Med. 127, 177-185.
163. Monestier, M., Kandiah, D. A., Kouts, S., Novick, K. E., Ong, G. L., Radic, M. Z., and Krilis, S. A. (1996). Monoclonal antibodies from NZWx BXSB/F1 mice to β2-glycoprotein I and cardiolipin: Species specificity and charge-dependent binding. J. Immunol. 156, 2631-2641.
164. Mor, F., Beigel, Y., Inbal, A., Goren, M., and Wysenbeek, A. J. (1989). Hepatic infarction in a patient with the lupus anticoagulant. Arthritis Rheum. 32, 491-495.
165. Mori, T., Takeya, H., Nishioka, J., Gabazza, E. C., and Suzuki, K. (1996). β2-glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Thromb. Haemostasia 75, 49-55.
166. Morton, K. E., Gavaghan, T. P., Krilis, S. A., Daggard, G. E., Baron, D. W., Hickie, J. B., and Chesterman, C. N. (1986). Coronary artery bypass graft failure: An autoimmune phenomenon? Lancet 2, 1353-1356.
167. Nicholls, A., Sharp, K. A., and Honig, B. (1991). Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 11,281-296.
168. Nilsson, I. M., Astedt, B., Hedner, U., and Berezin, D. (1975). Intrauterine death and circulating anticoagulant, "antithromboplastin." Acta. Med. Scand. 197, 153-159.
169. Nimpf, J., Bevers, E. M., Bomans, P. H. H., Till, U., Wurm, H., Kostner, G. M., and Zwaal, R. F. A. (1986). Prothrombinase activity of human platelets is inhibited by β2-glycoprotein I. Biochim. Biophys. Acta. 884, 142-149.
170. Nonaka, M., Matsuda, Y., Shiroishi, T., Moriwaki, K., Nonaka, M., and Natsuume-Sakai, S. (1992). Molecular cloning of mouse β2-glycoprotein I and mapping of the gene to chromosome 11. Genomics 13, 1082-1087.
171. Norman, D. G., Barlow, P. N., Baron, M., Day, A. J., Sim, R. B., and Campbell, I. D. (1991). Three-dimensional structure of a complement control protein module in solution. J. Mol Biol. 219, 717-725.
172. Oosting, J. D., Derksen, R. H. W. M., Bobbink, I. W., Hackeng, T. M., Bouma, B. N., and de Groot, P. G. (1993). Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism? Blood 81, 2618-2625.
173. Oosting, J. D., Derksen, R. H. W. M., Entjes, H. T. I., Bouma, B. N., and de Groot, P. G. (1992). Lupus anticoagulant activity is frequently dependent on the presence of β2-glycoprotein I. Thromb. Haemostasis 67, 499-502.
174. Oosting, J. D., Derksen, R. H. W. M., Hackeng, T. M., van Vliet, M., Preissner, K. T., Bouma, B. N., and de Groot, P. G. (1991). In-vitro studies of antiphospholipid antibodies and its cofactor, beta 2-glycoprotein I, show negligible effects on endothelial cell mediated protein C activation. Thromb. Haemostasis 66, 666-671.
175. Ostuni, P. A., Lazzarin, P., Pengo, V., Ruffatti, A., Schiavon, F., and Gambari, P. (1990). Renal artery thrombosis and hypertension in a 13 year old girl with antiphospholipid syndrome. Ann. Rheum. Dis. 49, 184-187.
176. Pengo, V., Biasiolo, A., Brocco, T., Tonetto, S., and Ruffatti, A. (1996). Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb. Haemostasis 75, 721-724.
177. Permpikul, P., Rao, L. V. M., and Rapaport, S. I. (1994). Functional and binding studies of the roles of prothrombin and β2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 83, 2878-2892.
178. Pierangeli, S. S., Harris, E. N., Gharavi, A. E., Goldsmith, G., Branch, D. W., and Dean, W. L. (1993). Are immunoglobulins with lupus anticoagulant activity specific for phospholipids? Br. J. Haematol. 85, 124-132.
179. Pierangeli, S. S., Liu, S. W., Anderson, G., Barker, J. H., and Harris, E. N. (1996). Thrombogenic properties of murine anti-cardiolipin antibodies induced by beta 2-g]yeoprotein I and human immunoglobulin G antiphospholipid antibodies. Circulation 94, 1746-1751.
180. Piette, J. C., Cacoub, P., and Wechsler, R. (1994). Renal manifestations of the antiphospholipid syndrome. Semin. Arthritis Rheum. 23, 357-366.
181. Polz, E. (1979). Isolation of a specific lipid-binding protein from human serum by affinity chromatography using heparin-sepharose. In "Protides of Biological Fluids" (H. Peeters, ed.), pp. 817-820. Pergamon Press, Oxford, England.
182. Pomeroy, C, Knodell, R. G., Swain, W. R., Arneson, P., and Mahowald, M. L. (1984). Budd-Chiari syndrome in a patient with a lupus anticoagulant. Gastroenterology 86, 158-161.
183. Ptitsyn, O. B., and Finkelstein, A. V. (1983). Theory of protein secondary structure and algorithm of its prediction. Biopolymers 22, 15-25.
184. Puurunen, M., Jokiranta, S., Vaarala, O., and Meri, S. (1995). Lack of functional similarity between complement factor H and anticardiolipin cofactor, β2-glycoprotein I (apolipoprotein H). Scand. J. Immunol. 42, 547-550.
185. Puurunen, M., Manttari, M., Manninen, V., Tenkanen, L., Alfthan, G., Ehnholm, C., Vaarala, O., Aho, K., and Palosuo, T. (1994). Antibody against oxidised low-density lipoprotein predicting myocardial infarction. Arch. Intern. Med. 154, 2605-2609.
186. Rao, L. V. M., Hoang, A. D., and Rapaport, S. I. (1995). Differences in the interactions of lupus anticoagulant IgG with human prothrombin and bovine prothrombin. Thromb. Haemostasis 73, 668-674.
187. Rauch, J., and Janoff, A. S. (1990). Phospholipid in the hexagonal II phase is immunogenic: Evidence for immunorecognition of nonbilayer lipid phases in vivo. Proc. Natl. Acad. Sci. USA 87, 4112-4114.
188. Rauch, J., and Janoff, A. S. (1992). The nature of antiphospholipid antibodies.J. Rheumatol. 19, 1782-1785.
189. Rauch, J., Tannenbaum, M., and Fortin, P. R. (1997). Inhibition of lupus anticoagulant activity by hexagonal phase (II) phosphatidylethanolamine requires prothrombin as a cofactor. Arthritis Rheum 40(9), Suppl., 105. [Abstract 445]
190. Rauch, J., Tannenbaum, M., and Janoff, A. S. (1989). Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids. Thromb. Haemostasis 62, 892.
191. Reber, G., Arvieux, J., Comby, E., Degenne, D., de Moerloose, P., Sanmarco, M., and Potron, G. (1995). Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. Thromb. Haemostasis 73, 444-452.
192. Reid, K. B. M., and Day, A. J. (1989). Structure-function relationships of the complement components. Immunol. Today 10, 177-180.
193. Roch, B., Khamashta, M. A., Atsumi, T., Bertolaccini, M. L., Amengual, O., and Hughes, G. R. V. (1997). Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome (APS). Arthritis Rheum. 40(9), Suppl., 300. [Abstract 1617]
194. Roldan, C. A., Shively, B. K., Lau, C. C., Gurule, F. T., Smith E. A., and Crawford, M. H. (1992). Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies. J. Am. Coll. Cardiol. 20, 1127-1134.
195. Rost, B., and Sander, C. (1993). Prediction of protein secondary structure at better than 70% accuracy. J. Mol. Biol. 232, 584-599.
196. Roubey, R. A. S., Eisenberg, R. A., Harper, M. F., and Winfield, J. B. (1995). Anticardiolipin autoantibodies recognize β2-glycoprotein I in the absence of phospholipid: Importance of Ag density and bivalent binding. J. Immunol. 154, 954-960.
197. Roubey, R. A. S., Pratt, C. W., Buyon, J. P., and Winfield, J. B. (1992). Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon β2-glycoprotein I. J. Clin. Invest. 90, 1100-1104.
198. Salemme, F. R. (1976). A hypothetical structure for an intermolecular electron transfer complex of cytochromes c and b5. J. Mol. Biol. 102, 563-568.
199. Sali, A., and Blundell, T. L, (1993). Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779-815.
200. Sali, A., Matsumoto, R., McNeil, H. P., Karplus, M., and Stevens, R. L. (1993). Three-dimensional models of four mouse mast cell chymases: Identification of proteoglycan binding regions and protease-specific antigenic epitopes. J. Biol. Chem. 268, 9023-9034.
201. Salonen, J. T., Yla-Herttuala, S., Yamamoto, R., Butler, S., Korpela, H., Salonen, R., Nyyssonen, K., Palinski, W., and Witztum, J. L. (1992). Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339, 883-887.
202. Sanchez, R., and Sali, A. (1997a). Evaluation of comparative protein structure modeling by (MODELLER-3). Proteins, suppl. 1, 50-58.
203. Sanchez, R., and Sali, A. (1997b). Advances in comparative protein-structure modeling Curr. Opin. Struct. Biol. 7, 206-214.
204. Sanghera, D. K., Wagenknecht, D. R., Mclntyre, J. A., and Kamboh, M. I. (1997). Identification of structural mutations in the fifth domain of apolipoprotein H (beta 2-glycoprotein I) which affect phospholipid binding. Hum. Mol. Genet. 6, 311-316.
205. Schousboe, I. (1988). In vitro activation of the contact activation system (Hageman factor system) in plasma by acidic phospholipids and the inhibitory effect of beta 2-glycoprotein I on this activation. Int. J. Biochem. 20, 309-315.
206. Schousboe, I., and Rasmussen, M. S. (1995). Synchronized inhibition of the phospholipid mediated autoactivation of factor XII in plasma by β2-glycoprotein I and anti-β2-glycoprotein I. Thromb. Haemostasis 73, 798-804.
207. Schultze, H. E., Heide, K., and Haupt, H. (1961). Uber einbisher unbekanntes niedermole kulares β2 globulin des human serums. Naturwissen Schaften 48, 719-724.
208. Schwab, E. P., Schumacher, R., Jr., Freundlich, B., and Callegari, P. E. (1993). Pulmonary alveolar haemorrhage in systemic lupus erythematosus. Semin. Arthritis Rheum. 23,8-15.
209. Scott, J. (1991). Lipoprotein(a). Thrombotic and atherogenic. Br. Med. J. 303, 663-664.
210. Scott, R. A. H. (1987). Anti-cardiolipin antibodies and pre-eclampsia. Br. J. Obstet. Gynaecol. 94, 604-605.
211. Seleznick, M. J., Silveira, L. H., and Espinoza, L. R. (1991). Avascular necrosis associated with anticardiolipin antibodies.J. Bheumatol. 18, 1416-1417.
212. Sellar, G. C, Keane, J., Mehdi, H., Peeples, M. E., Browne, N., Whitehead, A. S., Ackers, G. K., and Smith, F. R. (1985). Annu. Rev. Biochem. 54, 597-629.
213. Sheng, Y., Herzog, H., and Krilis, S. A. (1997). Cloning and characterization of the gene encoding the mouse β2-glycoprotein I. Genomics 41, 128-130.
214. β2-glycoprotein I antibody affinity. J. Immunol, in press.
215. Sheng, Y., Sali, A., Herzog, H., Lahnstein, J., and Krilis, S. A. (1996). Site-directed mutagenesis of recombinant human β2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. J. Immunol. 157, 3744-3751.
216. Shi, W., Krilis, S. A., Chong, B. H., Gordon, S., and Chesterman, C. N. (1990). Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust. N.Z. ]. Med. 20, 231-236.
217. Shi, W., Chong, B. H., Hogg, P. J., and Chesterman, C. N. (1993). Anticardiolipin antibodies block the inhibition by β2-glycoprotein I of the factor Xa generating activity of platelets. Thromb. Haemostasis 70, 342-345.
218. Silver, R. M., Smith, L. A., Edwin, S. S., Oshiro, B. T., Scott, J. R., and Branch, D. W. (1997). Variable effects on murine pregnancy of immunoglobulin G fractions from women with antiphospholipid antibodies. Am. J. Obstet. Gynaecol. 177, 229-233.
219. Simantov, R., LaSala, J. M., Lo, S. K., Gharavi, A. E., Sammaritano, L. R., Salmon, J. E., and Silverstein, R. L. (1995). Activation of cultured vascular endothelial cells by antiphospholipid antibodies.J. Clin. Invest. 96,2211-2219.
220. Smirnov, M. D., Triplett, D. T., Comp, P. C., Esmon, N. L., and Esmon, C. T. (1995). On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J. Clin. Invest. 95, 309-316.
221. Sneddon, I. B. (1965). Cerebral vascular lesion in livedo reticularis. Br. J. Dermatol. 77, 180-185.
222. Sorice, M., Circella, A., Griggi, T., Garofalo, T., Nieodemo, G., Pittoni, V., Pontieri, G. M., Lenti, L.,and Valesini, G. (1996). Anticardiolipin and anti-β2-GPI are two distinct populations of autoantibodies. Thromb. Haemostasis 75, 303-308.
223. Stafford-Brady, F. J., Urowitz, M. B., Gladman, D. D., and Easterbrook, M. (1988). Lupus retinopathy: Patterns, associations, prognosis. Arthritis Rheum. 31, 1105-1110.
224. Steinkasserer, A., Estaller, C., Weiss, E. H., Sim, R. B., and Day, A. J. (1991). Complete nucleotide and deduced amino acid sequence of human β2 glycoprotein I. Biochem. J. 277, 387-391.
225. Steinkasserer, A., Barlow, P. N., Willis, A. C, Kertesz, Z., Campbell, I. D., Sim, R. B., and Norman, D. G. (1992). Activity, disulphide mapping and structural modelling of the fifth domain of human β2-glycoprotein I. FEBS Lett. 313, 193-197.
226. Sugi, T., and Mclntyre, J. A. (1995). Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood 86, 3083-3089.
227. Sugi, T., and Mclntyre, J. A. (1996). Autoantibodies to kininogen-phospharidylethanolamine complexes augment thrombin-induced platelet aggregation. Thromb. Res. 84, 97-109.
228. Takeya, H., Mori, T., Gabazza, E. C, Kuroda, K., Deguchi, H., Matsuura, E., Ichikawa, J. K., Koike, T., and Suzuki, K. (1997). Anti-β2-glycoprotein I monoclonal antibodies with lupus anticoagulant-like activity enhance the β2-glycoprotein I binding to phospholipids. J. Clin. Invest. 99, 2260-2268.
229. Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., McShane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., and Winchester, R. J. (1982). The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25, 1271-1277.
230. Tincani, A., Spatola, L., Prati, E., Allegri, F., Ferremi, P., Cattaneo, R., Meroni, P., and Balestrieri, G. (1996). The anti-β2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native β2-glycoprotein I and preserved during species' evolution. J. Immunol. 157, 5732-5738.
231. Triplett, D. A. (1995). Antiphospholipid-protein antibodies: Laboratory detection and clinical relevance. Thromb. Res. 78, 1-31.
232. Triplett, D. A. (1996). Antiphospholipid-protein antibodies: Clinical use of laboratory test results (identification, predictive value, treatment). Haemostasis 26(Suppl. 4), 358-367.
233. Tuveson, D. A., Aheam, J. M., and Matsumoto, A. K. (1991). Molecular interactions of complement receptors on B lymphocytes: A CR1/CR2 complex distinct from the CR2/ CD19 complex.J. Exp. Med. 173, 1083-1089.
234. Vaarala, O. (1997). Atherosclerosis in SLE and Hughes syndrome. Lupus 6, 489-490.
235. Vaarala, O., Alfthan, G., Jauhiainen, M., Leirisalo-Repo, M., Aho, K., and Palosuo, T. (1993). Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341, 923-925.
236. Vaarala, O., Manttari, M., Manninen, V, Tenkanen, L., Puurunen, M., Aho, K., and Palosuo, T. (1995). Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 91, 23-27.
237. Vaarala, O., Puurunen, M., Manttari, M., Manninen, V., Aho, K., and Palosuo, T. (1996). Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb. Haemostasis 75, 456-459.
238. Vela, P., Battle, E., Salas, E., and Mareo, P. (1991). Primary antiphospholipid syndrome and osteonecrosis. Clin. Exp. Rheumatol. 9, 545-549.
239. Verrot, D., San-Marco, M., Dravet, C, Genton, P., Disdier, P., Bolla, G., Hade, J.-R., Reynaud, L., and Weiller, P.-J. (1997). Prevalence and significance of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am. ]. Med. 103, 33-37.
240. Vianna, J. L., Khamashta, M. A., Ordi-Ros, J., Font, J., Cervera, R., Lopez-Soto, A., Tolosa, C, Franz, J., Selva, A., Ingelmo, M., Vilardell, M., and Hughes, G. R. V. (1994). Comparison of the primary and secondary antiphospholipid syndrome: A european multicenter study of 114 patients. Am. J. Med. 96, 3-9.
241. Viard, J. P., Amoura, Z., and Bach, J. F. (1992). Association of anti-β2-glycoprotein-I antibodies with lupus-type circulating anticoagulants and thrombosis in systemic lupus erythematosus. Am. J. Med. 93, 181-186.
242. Vlachoyiannopoulos, P. G., Tektonidou, M., Petrovas, C, Krilis, S. A., and Moutsopoulos, H. M. (1998). Antibodies to β2-glycoprotein I: Avidity, binding specificity and association with thrombosis. Submitted for publication.
243. Walsh, M. T., Watzlawick, H, Putnam, F. W., Schmid K., and Brossmer, R. (1990). Effect of the carbohydrate moiety on the secondary structure of β2-glycoprotein I: Implications for the biosynthesis and folding of glycoproteins. Biochemistry 29, 6250-6257.
244. Wang, C. R., Hsieh, H. C, Lee, G. L., Chuang, C. Y., and Chen, C. Y. (1992). Pancreatitis related to antiphospholipid antibody syndrome in a patient with systemic lupus erythematosus.J. Rheumatol. 19, 1124-1125.
245. Wang, M. X., Kandiah, D. A., Ichikawa, K., Khamashta, M., Hughes, G. R. V., Koike, T., Roubey, R. A., and Krilis, S. A. (1995). Epitope specificity of monoclonal anti-β2-glycoprotein I antibodies derived from patients with the antiphospholipid syndrome. J. Immunol. 155, 1629-1636.
246. Willems, G. M., Janssen, M. P., Pelsers, M. M., Comfurius, P., Galli, M., Zwaal, R. F. A., and Bevers, E. M. (1996). Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes. Biochemistry 35, 13833-13842.
247. Woodard, C, Brey, R. L., Hart, R. G., and Kagan-Hallet, K. (1991). Neuropathologieal findings in stroke associated with antiphospholipid antibodies. Neurology 41, 296.
248. Wurm, H. (1984). Beta 2-glycoprotein I (apolipoprotein H) interactions with phospholipid vesicles. Int. J. Biochem. 16, 511-515.
249. Yamazaki, M., Asakura, H., Jokaji, H., Saito, M., Uotani, C, Kumabashiri, I., Morishita, E., Aoshima, K., Ikeda, T., and Matsuda, T. (1994). Plasma levels of lipoprotein(a) are elevated in patients with the antiphospholipid sundrome. Thromb. Haemostasis 71, 424-427.
250. Yang, C. D., Chen, S. L., Shen, N., Pei, J., Xue, F., Lu, Y., Gu, W., and Bao, C. D. (1997). The fifth domain of β2-glycoprotein I contains antigenic epitopes recognised by anticardiolipin antibodies derived from patients with the antiphospholipid syndrome. APLARJ. Rheumatol. 1,96-100.
251. Yin, E. T., and Gaston, L. W. (1965). Purification and kinetic studies on a circulating anticoagulant in a suspected case of lupus erythematosus. Thromb. Diath. Haemorrh. 14, 88.
252. Ziporen, L., Goldberg, I., Arad, M, Hojnik, M., Ordi-Ros, J., Afek, A., Blank, M., Sandbank, Y., Vilardell-Tarres, M., de Torres, I., Weinberger, A., Asherson, R. A., Kopolovic, Y., and Shoenfeld, Y. (1996). Libman-Sachs endocarditis in the antiphospholipid syndrome: Immunopathologic findings in deformed heart valves. Lupus 5, 196-205.
253. Ziporen, L., Shoenfeld, Y., Levy, Y., and Korczyn, A. D. (1997). Neurological dysfunction and hyperactive behaviour associated with antiphospholipid antibodies. J. Clin. Invest. 100, 613-619.